Navigation Links
Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial
Date:2/11/2008

response trials announced to the market on December 14th, 2006, confirmed that when given orally, Phospha E(R) significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease. Additionally, the most appropriate dosage required to commence human clinical trials was also determined. In these trials, animals treated with varying doses of Phospha E(R) were shown to have statistically significant reductions in key parameters such as plaque formation, aortic vascular dysfunction, cholesterol, triglycerides and LDL-C (so-called bad cholesterol).

About Metabolic Syndrome

Metabolic syndrome is characterised by a group of metabolic risk factors - - abdominal obesity and elevated blood pressure, cholesterol, triglycerides and blood glucose. The root causes of metabolic syndrome are overweight/obesity, physical inactivity, and genetic factors. It is estimated that about 27% of adults in the US have metabolic syndrome and that one in three overweight or obese people in the US have this condition. The condition is being diagnosed with increasing frequency.

About Phospha E(R)

Phospha E(R) is a patented derivative of vitamin E that has superior properties compared to its parent molecule. For example, Phospha E(R) has been shown to be better absorbed than vitamin E, both orally and through the skin, to lower cholesterol and triglycerides, prevent the formation of plaque in heart arteries, as well as having unique anti-inflammatory properties.

Phospha E(R) has applications across all three nutraceutical market segments, and is currently sold internationally as a dietary supplement by NBTY Inc (under the name of Ester-E(TM)) and is marketed worldwide in the personal care market as Vital ET(TM) by ISP Corporation.

Safe Harbor Statement

This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurat
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... CITY , Aug. 27, 2014 Varian Medical ... expand its current Salt Lake City ... underway outside of Utah to ultimately ... the next 20 years. " Utah ... and technical talent, many of whom can be credited with ...
(Date:8/27/2014)... 27, 2014   Los Angeles orthodontics expert, ... to patients who want to make their treatment even ... the OrthoSpaceship, all patients have a powerful tool to ... can be used by most patients with all types ... by using the AcceleDent® Aura system for a few ...
(Date:8/27/2014)... August 27, 2014 According ... Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current Trends, ... MarketsandMarkets, the global Dental Equipment Market is expected to ... in 2014, growing at a CAGR of 5.7% ... market data tables and 61 figures spread through ...
Breaking Medicine Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 4Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3
... 22, 2011 Mylan Inc. (Nasdaq: MYL ... of the Mylan Institutional business, has entered a license ... treatment products company, for the exclusive U.S. distribution rights ... Netherlands, has a portfolio that includes products used by ...
... 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... today that they have entered into a long-term ... of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class ... Peyronie,s disease.  Under the terms of the agreement, ...
Cached Medicine Technology:Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio 2Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 2Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 3Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 4Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 5Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 6Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan 7
(Date:8/28/2014)... 28, 2014 Registration is now open ... Warriors® in Holmdel, New Jersey on Sunday, October 19, ... the New Jersey Vietnam Veterans’ Memorial adjacent to the ... Bank Arts Center. All proceeds of the event will ... to restoring a sense of self, restoring the family ...
(Date:8/28/2014)... 2014 An unprecedented service that finds local ... 9 Spine offers their resources online and in person. ... a brick wall of discouragement as activities and hobbies are ... Cloud 9 Spine offers a refreshing plan of action. ... interaction that sets Cloud 9 Spine apart from other service ...
(Date:8/28/2014)... Alpine, NJ resident Othon Mourkakos is proud to ... Tiaras, to benefit the Immune Deficiency Foundation (IDF) Walk ... in Foley Square, New York. IDF is the ... (PI) are a group of more than 200 rare, ... immune system is missing or functions improperly. In ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 The ... the healthcare industry from the time a patient books ... and insurance company provide final payments for services rendered ... based medical billing service has the RCM process ... software programs and computers become common place in nearly ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 2Health News:Tips on Automating the Revenue Cycle Process with Medical Billing 3Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2
... able to stop or even slightly improve the progression ... to implant // embryonic cells into their brains, say ... that helps control movement. People with Parkinson’s don’t produce ... in people with the condition. ,Researchers compared 20 ...
... of Pittsburgh Medical Center treated 33 prostate cancer patients, ... Patients received the same radiation doses that patients in ... study show the elderly patients had a five-year survival ... patients experienced no unusual or prolonged breaks in treatment ...
... to cancer-causing pollutants found in the air, report researchers ... .Past studies in mice have shown exposure to pollutants ... the fact the placenta filters out most of the ... in humans. ,Researchers collected blood samples from 265 ...
... United States suffer from erectile dysfunction. This causes a ... and weight loss // , obese men with erectile ... say researchers. ,Researchers, conducted a study to determine ... increase in physical activity, would improve obese men’s erectile ...
... not decrease, but may increase, the risk for dementia ... an association between postmenopausal estrogen use and lower risk ... estrogen plus progestin in women aged 65 to 79 ... estrogen-only trial, researchers found 47 participants were diagnosed with ...
... 20s could reduce the risk of developing high blood pressure ... with spikes in blood pressure are more likely to have ... ,Specialists say assessing blood pressure changes in response to stress ... risk of high blood pressure. In a large study more ...
Cached Medicine News:
Patient-Centered Therapy that promotes natural cardiac function....
The ACP 215 is the automated closed system cell processor with integrated process control....
... Durability for Excellent Access. Access ... challenging cases. PT² wires combine ... linear elastic nitinol distal core ... tip. This provides excellent access ...
... The PCS2 system ... for the collection of ... allow for the collection ... platelet-poor plasma, platelet-poor plasma ...
Medicine Products: